Regeneron Pharmaceuticals company profile

REGN · NASDAQ · USD

Compare Regeneron Pharmaceuticals
$957.76Change from previous close: +0.56%Absolute change: +$5.36

Close · November 17, 2026

Company profile

Regeneron Pharmaceuticals has 15,410 employees and is headquartered in Tarrytown, United States.

Its product line begins with EYLEA injections, used for wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinopathy of prematurity. The company also offers Dupixent for atopic dermatitis and asthma, Libtayo for metastatic or locally advanced cutaneous squamous cell carcinoma, Praluent for heterozygous familial hypercholesterolemia and Kevzara for rheumatoid arthritis. Its development work extends to cancer, hematologic conditions and rare diseases, and its partners include Bayer on EYLEA, Alnylam on RNA interference therapeutics, Intellia on CRISPR/Cas9 gene editing and Sanofi on long-acting immunology antibodies. Its medicines are marketed worldwide.

In the fiscal year ended December 2025, revenue reached 14.3 billion US dollars, a 1.0% increase on the previous year, and net income was 4.5 billion US dollars. The company employs 15,410 people and is headquartered in Tarrytown, New York. It was incorporated in 1988.

Company facts

Industry
Biotechnology
Headquarters
777 Old Saw Mill River Road, 10591-6707, Tarrytown
Employees
15,410
Chief executive
Leonard Schleifer
Founded
1988
Fiscal year
January - December
Listing
REGN · NASDAQ
Currency
USD
ISIN
US75886F1075

Regeneron Pharmaceuticals and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Regeneron PharmaceuticalsREGNUnited States$98.52B15,41030.4%21.1
ModernaMRNAUnited States$87.1B4,700-80.8%—
Vertex PharmaceuticalsVRTXUnited States$135.44B6,40037.8%34.4
argenxARGXUnited States$59.8B1,86331.9%32.9
BeOne MedicinesONCUnited States$46.98B12,00017.8%52.7
Royalty PharmaRPRXUnited States$39.4B10064.4%45.4

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Regeneron Pharmaceuticals with its competitors